Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood

Behavioural Pharmacology

Volumn 19, Issue 5-6, 2008, Pages 641-649

  Perkins, Kenneth A ^a,e   Lerman, Caryn ^b   Grottenthaler, Amy ^a   Ciccocioppo, Melinda M ^a   Milanak, Melissa ^a   Conklin, Cynthia A ^a   Bergen, Andrew W ^c   Benowitz, Neal L ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c SRI INTERNATIONAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Dopamine; Genetics; Human; Mood; Reinforcement; Smoking reward

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; NICOTINE; OPIATE RECEPTOR; PLACEBO; SEROTONIN TRANSPORTER; ANKK1 PROTEIN, HUMAN; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; DRD3 PROTEIN, HUMAN; DRD4 PROTEIN, HUMAN; MU OPIATE RECEPTOR; OPRM1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SLC6A3 PROTEIN, HUMAN; SLC6A4 PROTEIN, HUMAN; TAQ POLYMERASE; UNCLASSIFIED DRUG;

ADULT; ANKK1 GENE; ARTICLE; CORRELATION ANALYSIS; DRD2 GENE; DRD4 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; OPRM1 GENE; REINFORCEMENT; REWARD; SLC6A3 GENE; SMOKING; VARIABLE NUMBER OF TANDEM REPEAT; AFFECT; ALLELE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENETICS; LEARNING; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO DEPENDENCE;

ADULT; AFFECT; ALLELES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; MINISATELLITE REPEATS; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; RECEPTORS, OPIOID, MU; REINFORCEMENT (PSYCHOLOGY); REWARD; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SET (PSYCHOLOGY); SMOKING; TAQ POLYMERASE; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 58149348752     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32830c367c     Document Type: Article

References (53)

1. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG (2004). Interacting effects of genetic predisposition and depression on adolescent smoking progression. Amer J Psychiatr 161:1224-1230.
2. Baker TB, Piper ME, McCarthy D, Majeskie MR, Fiore MC (2004). Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 111:33-51.
3. Berridge KC (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacol 191:391-431.
4. Conklin CA, Perkins KA (2005). Subjective and reinforcing effects of smoking during negative mood induction. J Abnormal Psychol 114:153-164.
5. David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC (2007a). The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nic Tobacco Res 9:225-231.
6. David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, et al. (2007b). Bupropion efficacy for smoking cessation is influenced by the DRD2 TaqIA polymorphism: analysis of pooled data from two clinical trials. Nic Tobacco Res 9:1251-1257.
7. David SP, Munafo MR, Murphy MF, Proctor M, Walton RT, Johnstone EC (2008). Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomized clinical trial of transdermal nicotine patch. Pharmacogenom J 8:122-128 [Epub 27 Mar 2007].
8. Diener E, Emmons RA (1984). The independence of positive and negative affect. J Pers Soc Psychol 47:1105-1117.
9. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH (2004). Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenom J 4:102-109.
10. Everitt BJ, Robbins TW (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
11. Fallon JH, Keator DB, Mbogori J, Turner J, Potkin SG (2004). Hostility differentiates the brain metabolic effects of nicotine. Cog Brain Res 18:142-148.
12. George SR, Cheng R, Nguyen T, Israel Y, O'Dowd BF (1993). Polymorphisms of the D4 dopamine receptor alleles in chronic alcoholism. Biochem Biophys Res Commun 196:107-114.
13. Gilbert DG (1997). The situation x trait adaptive response (STAR) model of drug use, effects, and craving. Human Psychopharmacol 12:S89-S102.
14. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O (1991). The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addiction 86:1119-1127.
15. Hu S, Brody CL, Fisher C, Gunzerath L, Nelson ML, Sabol SZ, et al. (2000). Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Mol Psychiatr 5:181-188.
16. Huitema BE (1980). Analysis of covariance and alternatives New York: John Wiley & Sons.
17. Hull JG, Bond CF (1986). Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis. Psychol Bull 99 :347-360.
18. Jamner LD, Jarvik ME, Shapiro D (1999). Nicotine reduces the frequency of anger reports in high but not low hostile smokers and nonsmokers: an ambulatory study. Exper Clin Psychopharmacol 7:454-463.
19. Juliano LM, Brandon TH (2002). Effects of nicotine dose, instructional set, and outcome expectancies on the subjective effects of smoking in the presence of a stressor. J Abnorm Psychol 111:88-97.
20. Kassel JD, Stroud LR, Paronis CA (2003). Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psychol Bull 129:270-304.
21. Lang PJ, Ohman A, Vaitl D (1988). The International Affective Picture System [Photographic Slides]. Gainesville, FL: the Center for Research in Psychophysiology, University of Florida
22. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG (1998). Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 17:56-62.
23. Lerman C, Caporaso NE, Audrain J, Main D, Boyd NR, Shields PG (2000). Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol Psychiatr 5:189-192.
24. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, et al. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541-548.
25. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, et al. (2004). The functional mu o pioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial Pharmacogenom J 4:184-192.
26. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231-242.
27. Lerman CE, Schnoll RA, Munafo MR (2007). Genetics and smoking cessation: improving outcomes in smokers at risk. Am J Prev Med 33 (6S):S398-S405.
28. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531.
29. Martin CS, Sayette MA (1993). Experimental design in alcohol administration research: limitations and alternatives in the manipulation of dosage-set. J Stud Alc 54:750-761.
30. Munafo MR, Clark TG, Johnstone EC, Murphy MFG, Walton RT (2004). The genetic basis for smoking behavior: a systematic review and meta-analysis. Nic Tobacco Res 6:583-597.
31. Munafò MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C (2006). Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 15:398-400.
32. Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC (2007). Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenom J 7:353-361.
33. Netter P, Hennig J, Huwe S, Olbrich R (1998). Personality related effects of nicotine, mode of application, and expectancies on performance, emotional states, and desire for smoking. Psychopharmacol 135:52-62.
34. Parrott AC (1998). Nesbitt's Paradox resolved? Stress and arousal modulation during cigarette smoking. Addiction 93:27-39.
35. Perkins KA, Grobe JE (1992). Increased desire to smoke during acute stress. Br J Addict 87:1037-1040.
36. Perkins KA, Grobe JE, Caggiula AC (1997). Acute reinforcing effects of low-dose nicotine nasal spray in humans. Pharmacol Biochem Behav 56:235-241.
37. Perkins KA, Sayette MA, Conklin CA, Caggiula AR (2003). Placebo effects of tobacco smoking and other nicotine intake. Nic Tobacco Res 5:695-709.
38. Perkins KA, Jacobs L, Ciccocioppo M, Conklin CA, Sayette M, Caggiula A (2004). The influence of instructions and nicotine dose on the subjective and reinforcing effects of smoking. Exper Clin Psychopharmacol 12:91-101.
39. Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, Caggiula AR (2006). Sex differences in the influence of nicotine and dose instructions on subjective and reinforcing effects of smoking. Psychopharmacol 184:600-607.
40. Perkins KA, Ciccocioppo M, Conklin C, Milanak M, Grottenthaler A, Sayette M (2008). Mood influences on acute smoking responses are independent of nicotine intake and dose expectancy. J Abnorm Psychol 117:79-93.
41. Pomerleau CS, Pomerleau OF (1987). The effects of a psychological stressor on cigarette smoking and subsequent behavioral and physiological responses. Psychophysiology 24:278-285.
42. Ray R, Jepson C, Patterson F, Strasser AA, Rukstalis M, Perkins K, et al. (2006). Association of OPRM1 Asn40Asp variant with the relative reinforcing value of nicotine in female smokers. Psychopharmacology 188:355-363.
43. Rose JE, Ananda S, Jarvik ME (1983). Cigarette smoking during anxiety-provoking and monotonous tasks. Addict Behav 8:353-359.
44. Schnoll RA, Johnson TA, Lerman C (2007). Genetics and smoking behavior. Curr Psychiatr Rep 9:349-357.
45. Shields P, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, Caporaso NE (1998). Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 7:453-458.
46. Shiffman S,Waters AJ (2004). Negative affect and smoking lapses: a prospective analysis. J Consult Clin Psychol 72:192-201.
47. Trummer O, Köppel H, Wascher TC, Grünbacher G, Gutjahr M, Stanger O, et al. (2006). The serotonin transporter gene polymorphism is not associated with smoking behavior. Pharmacogenom J 6:397-400.
48. Vandenbergh DJ, Bennett CJ, Grant MD, Strasser AA, O'Connor R, Stauffer RL, et al. (2002). Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. [see comment]. Nic Tobacco Res 4:333-340.
49. Westman EC, Behm FM, Rose JE (1996). Dissociating the nicotine and airway sensory effects of smoking. Pharmacol Biochem Behav 53:309-315.
50. Willner P, Jones C (1996). Effects of mood manipulation on subjective and behavioural measures of cigarette craving. Behav Pharmacol 7:355-363.
51. Zhang L, Kendler KS, Chen X (2006). The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct 2:28.
52. Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W (2005). Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:32618-32624.
53. Erratum in: J Biol Chem 2005; 280:38888.